ARTICLE | Clinical News
BMS-986036: Additional Ph II data
April 28, 2017 2:37 PM UTC
Additional data from a double-blind, U.S. Phase II trial in 68 evaluable NASH patients with a hepatic fat fraction of ≥10% showed that once-daily 10 mg and once-weekly 20 mg subcutaneous BMS-986036 fo...
BCIQ Target Profiles